6.
Al Riyami N, Al Khayari S, Al Zadjali R, Machado L, Al Madhani A, Al Lawati H
. Incidence, Risk Factors, Maternal and Neonatal Outcomes of Peripartum Cardiomyopathy (PPCM) in Oman. Glob Heart. 2023; 18(1):23.
PMC: 10162354.
DOI: 10.5334/gh.1198.
View
7.
Sliwa K, Skudicky D, Candy G, Bergemann A, Hopley M, Sareli P
. The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy. Eur J Heart Fail. 2002; 4(3):305-9.
DOI: 10.1016/s1388-9842(02)00008-9.
View
8.
Strasserking F, Musho J, Heimburger D, Mutale W, Damp J, Mumba N
. Peripartum cardiomyopathy: Characteristics and outcomes among women seen at a referral hospital in Lusaka, Zambia. Int J Cardiol Heart Vasc. 2022; 42:101104.
PMC: 9421395.
DOI: 10.1016/j.ijcha.2022.101104.
View
9.
Ricci F, De Innocentiis C, Verrengia E, Ceriello L, Mantini C, Pietrangelo C
. The Role of Multimodality Cardiovascular Imaging in Peripartum Cardiomyopathy. Front Cardiovasc Med. 2020; 7:4.
PMC: 7041418.
DOI: 10.3389/fcvm.2020.00004.
View
10.
Viljoen C, Hoevelmann J, Sliwa K
. Peripartum cardiomyopathy: risk factors and predictors of outcome. Curr Opin Cardiol. 2023; 38(3):223-232.
DOI: 10.1097/HCO.0000000000001037.
View
11.
Sugahara M, Kagiyama N, Hasselberg N, Blauwet L, Briller J, Cooper L
. Global Left Ventricular Strain at Presentation Is Associated with Subsequent Recovery in Patients with Peripartum Cardiomyopathy. J Am Soc Echocardiogr. 2019; 32(12):1565-1573.
PMC: 6899171.
DOI: 10.1016/j.echo.2019.07.018.
View
12.
Halkein J, Tabruyn S, Ricke-Hoch M, Haghikia A, Nguyen N, Scherr M
. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest. 2013; 123(5):2143-54.
PMC: 3638905.
DOI: 10.1172/JCI64365.
View
13.
Sliwa K, Petrie M, van der Meer P, Mebazaa A, Hilfiker-Kleiner D, Jackson A
. Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. Eur Heart J. 2020; 41(39):3787-3797.
PMC: 7846090.
DOI: 10.1093/eurheartj/ehaa455.
View
14.
Davis M, Jarvie J, Gambahaya E, Lindenfeld J, Kao D
. Risk Prediction for Peripartum Cardiomyopathy in Delivering Mothers: A Validated Risk Model: PPCM Risk Prediction Model. J Card Fail. 2021; 27(2):159-167.
DOI: 10.1016/j.cardfail.2020.12.022.
View
15.
Schutte J, Steegers E, Schuitemaker N, Santema J, de Boer K, Pel M
. Rise in maternal mortality in the Netherlands. BJOG. 2009; 117(4):399-406.
DOI: 10.1111/j.1471-0528.2009.02382.x.
View
16.
Sanusi M, Momin E, Mannan V, Kashyap T, Pervaiz M, Akram A
. Using Echocardiography and Biomarkers to Determine Prognosis in Peripartum Cardiomyopathy: A Systematic Review. Cureus. 2022; 14(6):e26130.
PMC: 9299948.
DOI: 10.7759/cureus.26130.
View
17.
Blauwet L, Delgado-Montero A, Ryo K, Marek J, Alharethi R, Mather P
. Right Ventricular Function in Peripartum Cardiomyopathy at Presentation Is Associated With Subsequent Left Ventricular Recovery and Clinical Outcomes. Circ Heart Fail. 2016; 9(5).
DOI: 10.1161/CIRCHEARTFAILURE.115.002756.
View
18.
Hilfiker-Kleiner D, Sliwa K
. Pathophysiology and epidemiology of peripartum cardiomyopathy. Nat Rev Cardiol. 2014; 11(6):364-70.
DOI: 10.1038/nrcardio.2014.37.
View
19.
Labbene I, Arrigo M, Tavares M, Hajjej Z, Brandao J, Tolppanen H
. Decongestive effects of levosimendan in cardiogenic shock induced by postpartum cardiomyopathy. Anaesth Crit Care Pain Med. 2016; 36(1):39-42.
DOI: 10.1016/j.accpm.2016.02.009.
View
20.
Heidenreich P, Bozkurt B, Aguilar D, Allen L, Byun J, Colvin M
. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022; 145(18):e895-e1032.
DOI: 10.1161/CIR.0000000000001063.
View